Progress of diagnosis and treatment of monoclonal gammopathy of neural significance

VernacularTitle:神经意义的单克隆免疫球蛋白血症诊治进展
Author: Jiayin SONG ¹ ; Zhongxia HUANG
Author Information

1. 首都医科大学附属北京朝阳医院西院血液与肿瘤科　北京市多发性骨髓瘤医疗研究中心，北京　100043
Keywords: Multiple myeloma; Monoclonal gammopathy of neural significance; Peripheral nervous system diseases; Diagnosis; Treatment
From: Journal of Leukemia & Lymphoma 2022;31(5):317-320
CountryChina
Language:Chinese
Abstract: Monoclonal gammopathy of neural significance (MGNS) belongs to the category of monoclonal gammopathy of clinically significance. It is an early-stage disease that mainly occurs in peripheral nerves and is not sufficient for the diagnosis of multiple myeloma or lymphoma. MGNS needs to be differentiated from neuropathies due to POEMS syndrome and light-chain amyloidosis; if necessary, nerve biopsy can be performed to clarify the relationship between peripheral nerve symptoms and lymphoplasmacytic disease. Treatment of MGNS is recommended to give intravenous gammaglobulin, plasma exchange and targeted anti-lymphoplasmacytic tumour therapy such as CD20 monoclonal antibody. Early recognition and intervention of MGNS, with multidisciplinary cooperation, will help to reduce the risk of malignancy and the incidence of disability.